Jan 13, 2025
THe Science Research diaries of S. Sunkavally, p398.
seen from United States
seen from Yemen
seen from Ukraine
seen from Malaysia
seen from United States
seen from United States
seen from United States
seen from United States
seen from France
seen from United States
seen from United States
seen from Italy
seen from United States
seen from Russia
seen from Australia
seen from Russia
seen from Yemen
seen from United States
seen from United States
seen from Yemen
THe Science Research diaries of S. Sunkavally, p398.
TSRNOSS. Page 195.
Desferrioxamine | Find why Desferrioxamine is prescribed including its typical usage, side effects, and safety, interactions, warnings and ask a doctor for expert advise on Desferrioxamine at MediKlik.com
Desferrioxamine | Find why Desferrioxamine is prescribed including its typical usage, side effects, and safety, interactions, warnings and ask a doctor for expert advise on Desferrioxamine at MediKlik.com
Read the full paper at: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=50082 DOI: 10.4236/ojneph.2014.43018 Author(s) Ankita Patel, Suchita Mehta, Ahmad Waseef, Subodh Saggi ABSTRACT Background: Anemia is a common complication of end-stage renal disease (ESRD) and is effectively managed by Erythropoietin Stimulating Agents (ESAs) and intravenous iron therapy. Management of anemia in ESRD patients with myelodysplastic syndrome (MDS) poses a unique challenge. ESAs even at extremely high doses do not result in a desired response, especially if the patients are iron-overloaded. Case: A 72-year-old man with history of ESRD and MDS on hemodialysis since September 2009 was severely anemic requiring massive doses of ESA in excess of 90,000 units/week. Iron saturation was consistently >60%; ferritin was >2500. Desferrioxamine (DFO) 125 mg IV/week was begun in November 2010. His PRBC transfusion and ESA requirements declined after the initiation of this therapy. He had 33 ER visits for PRBC transfusions (1 - 3 transfusions/visit) from September 2009 to November 2010 (average: 2.35/month), which decreased to 18 visits in 20 months (average: 0.9/month) after getting DFO. eww140930gjr Conclusion: We report a case of MDS with ESRD on hemodialysis where anemia was managed with Desferrioxamine therapy along with ESA, after which it was noted that there was a significant reduction in the number of PRBC transfusions that the patient received along with a decrease in ESA requirements and a decrease in number of hospitalizations, which in the long term could be cost effective. KEYWORDS Anemia, Desferrioxamine, ESRD